All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-02-05T16:09:35.000Z

Timeline of key drug approvals in MPN treatment


After reading, you'll be able to:
  • After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.
Share:
 0 minute

Bookmark this article

Over the past two decades, the therapeutic landscape of myeloproliferative neoplasms (MPN) has rapidly evolved in conjunction with innovative research and pioneering clinical trials. Identification of the key driver mutation in the JAK2 gene represented a milestone in the development of disease-specific therapies. As a result, patients now have access to four Janus kinase inhibitors for the treatment of myelofibrosis, with momelotinib most recently approved in September 2023. Furthermore, interferon treatments and specific cytoreductive therapies have improved clinical outcomes for patients diagnosed with essential thrombocythemia and polycythemia vera.

To showcase the progression of treatment options over the past 20 years, we present a visual summary of approvals for common therapies used in MPN treatment (Figure 1).

Figure 1. Timeline of drug approvals in MPN 

1 March 14th 1997, 2 May 24th 2000, 3 January 19th 2001, 4 June 20th 2002, 5 October 16th 2002, 6 August 29th 2004, 7 November 16th 2004, 8 June 29th 2007, 9 November 16th 2011, 10 August 23rd 2012, 11 December 4th 2014, 12 August 16th 2019, 13 February 2021, 14 February 28th 2022, 15 September 15th 2023

EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; IFN, interferon; JAK, Janus kinase; MF, myelofibrosis: OOD, orphan drug administration; PV, polycythemia vera.